Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
- 1 January 1997
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 29 (1), 66-71
- https://doi.org/10.1016/s0272-6386(97)90009-3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- In Advanced Renal Failure, Dietary Phosphorus Restriction Reverses Hyperparathyroidism Independent of Changes in the Levels of CalcitriolNephron, 1993
- Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolismKidney International, 1989
- Calcium acetate, an effective phosphorus binder in patients with renal failureKidney International, 1989
- Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing DialysisNew England Journal of Medicine, 1986
- Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.JCI Insight, 1984
- Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysisKidney International, 1982
- Gastrointestinal Absorption of Aluminum from Aluminum-Containing AntacidsNew England Journal of Medicine, 1977
- The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal diseaseKidney International, 1973
- HYPERCALCÆMIA AFTER ORAL CALCIUM-CARBONATE THERAPY IN PATIENTS ON CHRONIC HÆMODIALYSISThe Lancet, 1973
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJCI Insight, 1971